Core Viewpoint - Jiuyuan Gene (02566) experienced a stock price increase of over 7% following the release of its interim results, indicating market optimism despite a decline in financial performance [1] Financial Performance - For the six months ending June 30, 2025, Jiuyuan Gene reported revenue of RMB 639 million, a year-on-year decrease of 9.05% [1] - Gross profit was RMB 525 million, down 2.84% year-on-year [1] - Net profit attributable to shareholders was RMB 90.17 million, reflecting a decline of 14.4% compared to the previous year [1] - Earnings per share stood at RMB 0.37 [1] Market Dynamics - The overall revenue decline of 9.1% was attributed to a combination of internal and external factors [1] - Sales of orthopedic products increased by over 10% year-on-year, indicating growth in this segment [1] - The company is focusing on stabilizing existing markets and cultivating new ones through differentiated commercial policies to achieve steady annual revenue growth [1]
港股异动 | 九源基因(02566)绩后涨超7% 中期股东应占纯利9017.4万元 骨科领域产品销量同比增超10%